Multiple Treatments for Ebola Virus Disease (EVD)

• Status: Unknown status
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether multiple therapeutic regimens are effective in the treatment of Ebola Virus Disease (EVD)

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Clinical Research Management, Inc.
• Collaborators: Bill and Melinda Gates Foundation; Duke University; INC Research; Syneos Health; University of North Carolina; University of Sierra Leone
• Treatments: Atorvastatin; Atorvastatin Calcium; Azithromycin; Erlotinib Hydrochloride; Irbesartan; Sunitinib

Criteria

Inclusion Criteria:

• Males and females aged 6 months and >8kg in weight

• Confirmed case of EVD

• Admission to the hospital < 48 hours prior to enrollment

• Participant or family member/guardian able and willing to provide signed informed consent

Exclusion Criteria:

• Prior treatment with any other specific experimental anti-EVD product, or expectation to receive another experimental anti-EVD product during the course of the study (this does not include general supportive care or nutritional supplements routinely administered to all hospitalized patients with EVD)

• Unresponsive

• In the treating physicians opinion, an inability to comply with the study treatment regimen